Peptide–TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens

Journal: Nature Biotechnology

Published: 2020-01-13

DOI: 10.1038/s41587-019-0390-x

Affiliations: 12

Authors: 30

Go to article
Institutions Share
NIH NIAID Vaccine Research Center (VRC), United States of America (USA) 0.33
Avidea Technologies, Inc., United States of America (USA) 0.27
Curie Institute, France 0.08
Center of Clinical Investigations in Biotherapies of Cancer (CICBT), France 0.08
Fischell Department of Bioengineering, UMCP, United States of America (USA) 0.07
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, United States of America (USA) 0.07
NIH NIAID Research Technologies Branch (RTB), United States of America (USA) 0.03
Institute of Macromolecular Chemistry (IMC), CAS, Czech Republic 0.03
Oxford Department of Oncology, United Kingdom (UK) 0.03

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER